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T
 
wo articles in this issue consider the econom-
ics of deep vein thrombosis (DVT) prophy-
laxis in populations of patients at high risk for this
condition: Davies (pages 397–406) focuses on man-
aging surgical patients and Pechevis (pages 389–396)
reports on acutely ill patients. DVT constitutes a
major health problem that causes significant mor-
bidity and mortality. Major complications of DVT
include edema, ulceration, and pulmonary embo-
lism. In the United States, DVT occurs in about
two million individuals each year. About 600,000
patients develop pulmonary embolism annually in
the United States, and it is estimated that 60,000
individuals die each year as a result, placing this
condition among the top causes of death (Table 1)
[1,2].
DVT is the most common cause of preventable
death among hospitalized patients [3]. Surgical pa-
tients are at high risk of DVT, especially those un-
dergoing orthopedic surgery. Prophylaxis has been
shown to be clinically efficacious and to result in
significant risk reduction [4]; it is also the most ef-
fective way of reducing the burden of DVT. For ma-
jor orthopedic surgery such as hip surgery, DVT
prophylaxis is used increasingly on a routine basis
during hospitalization and a number of studies sug-
gest that it is highly cost-effective [5–7]. In this issue,
Davies explores the cost-effectiveness of extended
DVT prophylaxis after hospital discharge for pa-
tients undergoing hip surgery in the UK, comparing
prophylaxis with a low molecular weight heparin
(LMWH) only during hospital stay, to LMWH ad-
ministration both during hospital stay and for 21
days postdischarge. Extended thromboprophylaxis
resulted in increased costs for health care services
in most cases but was also associated with im-
proved survival and life years gained in all cases.
The cost per quality adjusted life year of extended
 
prophylaxis was estimated at £
 
5732 (approximately
US$8386), placing this intervention between kid-
ney transplant (£
 
4710/QALY; or $6891/QALY) and
breast cancer screening (£
 
5780/QALY; or $8456/
QALY). The limitations that the authors of this
paper mention with regard to their data sources
highlight the importance of using strong and ade-
quate data to build useful economic models. The
study nonetheless indicates potential added value
of thromboprophylaxis following discharge for hip
surgery. More than 40 million inpatient surgeries
are performed each year in the US [8], suggesting
that a cost-effective management of surgical pa-
tients at risk for DVT should be a more significant
consideration in health care decision-making.
DVT is also a major complication in serious
medical conditions such as cancer, heart failure,
myocardial infarction and stroke, and pulmonary
embolism is the most frequent cause of death asso-
ciated with childbirth [1,9]. Only one in four pa-
tients dying of pulmonary embolism has had re-
cent surgery, which emphasizes the importance of
prophylaxis in medical patients as well as surgical
[9]. In this issue, Pechevis et al. compare cost-effec-
tiveness of DVT prophylaxis in acutely ill medical
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Table 1
 
Number of deaths from selected causes in the 
United States in 1998 [1,2]
 
Cause of death Deaths per year
Acute myocardial infarction 204,000
Pneumonia 90,000
Diabetes 65,000
Pulmonary embolism 60,000
Breast cancer 42,000
Renal failure 24,000
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patients to no intervention. The model, based on
a clinical trial, suggests that for each thousand
acutely ill patients over 40 years of age, thrombo-
prophylaxis with enoxaparin could prevent be-
tween one and 10 deaths, and between 60 and
127 venous thromboembolic events, at an incre-
 
mental net cost ranging from 
 
€
 
35,857 (approxi-
mately $31,662, postphlebitis syndrome not con-
sidered) to net savings when disabling postphlebitis
syndrome is included in the model. The fact that
the results depends so much on whether or not
postphlebitis syndrome was included illustrates
how important it is to collect data and perform
analyses on all health outcomes attributable to an
intervention over patients’ remaining lifetime. It is
estimated that postphlebitis syndromes occur in
25% to 50% of DVT patients, with manifesta-
tions becoming apparent in the first two years af-
ter acute thrombosis for the great majority of pa-
tients [1]. This disabling condition should therefore
be considered in a long-term economic evaluation
of DVT management.
Both studies bring additional evidence to a body
of research data which indicates that broader appli-
cation of some form of DVT prophylaxis for moder-
ate to high-risk patients is cost-effective [10]. Despite
strong evidence of the efficacy of a wide variety of
prophylactic agents and a growing body of evi-
dence of the cost-effectiveness of thromboprophy-
laxis in moderate and high risk patients, this condi-
tion is plagued by suboptimal management [11].
Enhancing awareness, improving data sources and
providing further evidence as to whether DVT pro-
phylaxis in surgical and medical patients is cost-
effective are key steps towards improved manage-
ment of this important health condition.
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